Dr. Michael Murphy leads an invigorating panel discussion with a rare disease patient and other industry experts. Each share their experience with rare disease trials along with their thoughts on the road ahead in a post-COVID environment.

Discussion points include:

  • Balancing and improving the interest of the patients, site and sponsor
  • Connecting rare disease patients with medical experts for studies
  • Feasibility and the differences seen in rare disease trials
  • The importance of patient advocacy groups as an ancillary partner
  • Benefits and challenges of study visits for rare disease trial patients